Trial Profile

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With a Sublingual Formulation of Dexmedetomidine (BXCL501)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexmedetomidine (Primary)
Indications Post-traumatic stress disorders
Focus Therapeutic Use
Acronyms BASIS; RISE

Most Recent Events

08 Apr 2026 According to v media release, first patient has been enrolled in a U.S. Department of War (DoW)-funded.
08 Apr 2026 Status changed from not yet recruiting to recruiting.
11 Feb 2026 Planned initiation date changed from 29 Aug 2025 to 11 Feb 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com